In this piece, we’ll take a look at the 5 Biggest Neuroscience Companies in the World. For more such companies, go to 15 Biggest Neuroscience Companies in the World.
5. Roche Holding AG (OTC:RHHBY)
Market Cap as of January 07, 2023: $261.96 billion
Roche Holding AG (OTC:RHHBY) is a Swiss multinational biopharmaceutical and diagnostic firm. The company’s product portfolio includes therapies for cancer, virology, and autoimmune diseases, among others. Roche Holding AG (OTC:RHHBY) acquired Ventana Biotech, Inc. in 2008 to strengthen its diagnostic division and Genentech in 2009 to expand its portfolio of oncology pharmaceutical products. Roche Holding AG (OTC:RHHBY), along with its partners, is working on some of the most difficult-to-treat neurological diseases such as multiple sclerosis, spinal muscular atrophy (SMA), neuromyelitis optica spectrum disorder (NMOSD), Alzheimer’s diseases, and other rare diseases.
4. Pfizer Inc. (NYSE:PFE)
Market Cap as of January 07, 2023: $284.93 billion
Headquartered in New York, United States, Pfizer Inc. (NYSE:PFE) is an American multinational biotechnology and pharmaceutical firm. It is among the world’s largest pharmaceutical companies that offer medicines, medical devices, vaccines, and consumer healthcare products for inflammation, oncology, cardiovascular, and other therapeutic areas. The neurology segment of the company focuses on diseases like multiple sclerosis, transthyretin amyloidosis (ATTR), and other neurological disorders.
3. Merck & Co., Inc. (NYSE:MRK)
Market Cap as of January 07, 2023: $291.16 billion
Headquartered in New Jersey, United States, Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company that develops, manufactures, and markets a range of prescription drugs, vaccines, and other healthcare products. The company’s pharmaceutical products are focused on therapeutic areas such as infections, cardiometabolic diseases, cancer, etc. The company’s immuno-oncology platform is expanding as a significant contributor to total sales in the cancer market. The pharmaceutical side of the neuroscience segment of the company is focused on developing treatments for neurological disorders such as early-stage and advanced Alzheimer’s, depression, and schizophrenia. In early 2021, Merck & Co., Inc. (NYSE:MRK) announced a three-year collaboration with the Transylvanian institute of technology (TINS) to research and improve their understanding of information processing in the human brain which will be the key to overcoming the current limitations of artificial intelligence technology.
2. AbbVie Inc. (NYSE:ABBV)
Market Cap as of January 07, 2023: $294.54 billion
Founded in 2013, AbbVie Inc. (NYSE:ABBV) is a specialty biopharmaceutical corporation that operates in the discovery, development, manufacturing, and commercialization of drugs to treat chronic and complex disorders. The neuroscience segment of the company is focused on research and development of therapies to treat neurological disorders such as Alzheimer’s, major depressive disorder, bipolar disorder, migraine, stroke, post-stroke spasticity, Parkinson’s, schizophrenia, and other disorders related to the central nervous system. Namzaric, Depakote, Requip, and Zinbryta are examples of some of the company’s products.
1. Johnson & Johnson (NYSE:JNJ)
Market Cap as of January 07, 2023: $470.87 billion
Founded in 1886, Johnson & Johnson (NYSE:JNJ) is an American multinational company that is made up of three divisions: pharmaceutical, medical devices, and diagnostics. The company is among the world’s largest and most diverse healthcare firms that provide products and product-related services to customers and markets. In 1961, Johnson & Johnson (NYSE:JNJ) acquired Janssen Pharmaceuticals to strengthen its pharmaceutical division. Through an alliance with health and technology partner companies, Janssen Pharmaceuticals is working on improving its understanding of nervous system disorders to develop novel therapies for disorders like multiple sclerosis, depression, and schizophrenia. Invega is a product of the company used to treat schizophrenia.
Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also take a look at 10 Best Performing Actively Managed ETFs in 2022 and 10 Best Cryptocurrencies to Invest In.
